N early 50% of adult women may experience urinary incontinence, the involuntary loss of urine.
that have important implications for current clinical practice and constructed summary tables of that evidence for stress and urgency incontinence. The prospectively followed cohorts of these trials also provide the highest levels of evidence on the moderate-term safety and efficacy of the most common incontinence therapies for women. Because of the limited comparative efficacy trials across all available incontinence medications, we calculated the average reduction in urinary frequency, urgency incontinence episodes, and common adverse effects, using the trial evidence used for Food and Drug Administration (FDA) registration of the most commonly prescribed medications.
Detection and Evaluation of Incontinence

History
Many women do not volunteer incontinence symptoms to their primary care provider because of embarrassment, lack of knowledge, or misconception about treatment. 15, 16 Once incontinence is detected, the clinician should determine symptom severity and desire for treatment as early as possible. A general principle of care is the need to balance diagnostic certainty with the risk or invasiveness of therapy. In all women, the clinician should identify and treat reversible causes such as urinary tract infection, excessive fluid intake (>2 L/day), use or timing of medications that may worsen incontinence (ie, diuretics), and comorbid conditions contributing to incontinence (obesity, constipation, sleep apnea, tobacco use, dementia, and depression). The Box outlines signs or symptoms suggesting serious underlying pathology, such as cancer or serious neurologic disease, that should prompt immediate referral to an incontinence specialist. Most women do not require an extensive preliminary evaluation of urinary incontinence because initial noninvasive treatments may be begun without clear differentiation between the 2 most common urinary incontinence subtypes, stress and urgency incontinence. The history should focus on the onset, duration, severity, frequency and effect on quality of life. Figure 1 displays 3 simple items in a validated questionnaire to help clinicians discern the common incontinence subtypes. Briefly, the questionnaire describes various life situations and asks participants whether they experienced urinary incontinence during the past 3 months (even a small amount), whether they experienced involuntary urinary leaking, and when they experienced it most often. 17 Stress incontinence is characterized by involuntary loss of urine with increases in abdominal pressure such as exercise or coughing. The main etiology is a poorly functioning urethral closure mechanism and is associated with loss of anatomic support or trauma from vaginal childbirth, obesity, and situations that repetitively increase intra-abdominal pressure, such as chronic constipation, heavy lifting, and high-impact exercise.
18-23 Urgency incontinence is characterized by a sudden compelling desire to pass urine that is difficult to defer. 24 Affected women experience little warning before incontinence episodes and an increase in urinary frequency both day and night. In most women, urgency incontinence is idiopathic. However, it is common in a subset of women with systemic neurologic conditions (eg, Parkinson disease, multiple sclerosis, pelvic or spinal nerve injury). Overflow incontinence symptoms are similar to those of stress and urgency incontinence, but this type of incontinence is associated with incomplete emptying of the bladder. It is more common in women with underlying systemic neurologic disease or anatomic abnormalities such as urethral obstruction. Many women with incontinence experience coexisting stress and urgency symptoms, usually called mixed urinary incontinence. Recent urinary microbiome research shows that the diversity of the urinary microbiota in women with urgency incontinence may differ from the lactobacillus-predominant resident flora of continent adult women. [25] [26] [27] [28] Given the uncertain etiology and likely multifactorial nature of urgency incontinence, individualized treatment strategies are not yet available. Future research in this area may help characterize populations of women who may benefit most from specific therapies.
Examination
Guidelines from international and specialty organizations are largely consistent in their recommendations for the initial incontinence evaluation, which includes history, physical examination, urinary tract infection testing, urinary stress testing, and assessment of postvoid residual. [29] [30] [31] [32] [33] [34] Urinalysis should be used to identify urinary tract infection and detect hematuria, pyuria, or glycosuria because these may represent comorbid conditions associated with incontinence. When history taking and urinalysis do not provide a clear etiology of incontinence symptoms, a written voiding diary recording quantity and timing of fluid intake and urine output during 1 to 3 days can provide information about potential modifiable factors associated with incontinence episodes. Figure 2 displays diaries of common abnormal voiding patterns. Improved fluid intake patterns can reduce urgency and frequency symptoms in women who infrequently drink large volumes of liquids. More frequent, regular voiding can reduce symptoms in women who have infrequent, largevolume voids. Pelvic examination is recommended when findings, such as detection of a pelvic mass, would alter the planned intervention or influence treatment selection. In postmenopausal women, clinicians should look for vaginal atrophy, which can effectively be treated with vaginal estrogen. Pelvic examination may identify conditions requiring prompt referral (Box). In addition, clinicians should look for pelvic organ prolapse beyond the vagina because it is associated with a higher risk of urinary retention. For these patients, referral to a specialist for treatment addressing both prolapse and incontinence may be warranted. Clinicians can assess pelvic floor muscle integrity and function during the bimanual pelvic examination by asking the patient to contract her pelvic floor muscles (Figure 3) . Women who are unable to isolate pelvic floor muscles or who are unable to properly perform pelvic floor muscle contraction often benefit from supervised pelvic floor physical therapy instead of simple verbal instructions or handouts on pelvic exercises.
Additional Assessments
When the diagnosis is unclear or the initial treatment is unsuccessful, consultation with an incontinence specialist can determine whether additional diagnostic studies are needed. Current clinical guidelines offer different recommendations about the utility of these diagnostic tests. [29] [30] [31] [32] [33] [34] All clinicians can conduct the simple urinary stress test. While in the lithotomic or standing position, the patient strains or coughs with a comfortably full bladder while the clinician directly observes the urethra meatus for urine leakage. Leakage during these maneuvers is highly suggestive of stress incontinence (positive predictive value of 78% to 97%). 35 Urodynamic studies are not necessary in the evaluation of uncomplicated urinary incontinence or before every stress incontinence surgery. This conclusion is based on results of a multicenter randomized clinical trial of 630 women with stress urinary incontinence symptoms. In women with demonstrable stress incontinence, defined as a positive cough stress test result in the trial, a preoperative office evaluation provided a noninferior 12-month treatment outcome in women who underwent stress incontinence surgery. 36 Urodynamic testing is still used when specialists seek specific information about bladder and urethral physiology or to characterize urinary incontinence subtypes. Within 10 minutes after a measured void, a postvoid residual should be obtained by either catheterization or ultrasonography. There is no established normative value for postvoid residual. Experts consider less than 100 mL for voided volumes of greater than 200 mL or one-third of total voided volume as normal. Postvoid residual measurement is recommended when patients report incomplete voiding, have pelvic organ prolapse beyond the hymen, or will undergo stress urinary incontinence surgery. Assessment of the postvoid residual is not required before medication is prescribed for urgency incontinence. However, because these medications can cause urinary retention, clinicians should stop the medication and proceed with additional assessment if new or worsening bladder symptoms develop.
Evidence-Based Incontinence Treatment
Selection of treatment is based on the nature of the predominant symptom (stress vs urgency incontinence), a woman's goals and expectations for improvement or cure, her level of commitment to therapy, her tolerance of risk or adverse effects, and her financial situation. Some women prefer to attempt all conservative options before more invasive ones. Others may prioritize expediency or efficacy, accepting risks of surgery or more invasive approaches. Individual patient counseling should include information about expected symptom reduction, estimated time commitment, complications, and adverse effects, as well as expected out-of-pocket expense.
Behavior and Lifestyle Modification
Nearly all initial incontinence therapy should start with noninvasive measures because the benefits are associated with low risk and limited expense. Clinicians can offer these lifestyle modifications, including smoking cessation, regardless of the incontinence subtype. Management of constipation and avoidance of excessive fluids, with reduction in consumption of caffeine, carbonated beverages, diet beverages, and alcohol, should be discussed. 37 Fluidmanagement strategies promote frequent intake of small amounts of fluid (ie, 4-5 oz/hour) up to 2 L a day of predominantly water in lieu of large, episodic fluid intakes (ie, 36 oz in one drink). Timed voiding measures, or voiding at intervals that are tailored to each patient (typically every 2 to 3 hours) during the day, can reduce urgency incontinence episodes. Although systematic reviews do not provide strong evidence to support these strategies, in the authors' clinical experience, timed voiding and avoidance of excessive fluids are effective strategies, especially for patients with urgency incontinence. 38-40 Table 1 summarizes results of important, landmark, randomized trials about urgency incontinence. A multicenter randomized controlled trial evaluated the efficacy of supervised behavioral modification (including pelvic floor muscle exercise instruction, strategies to suppress urge, timed voiding, and fluid management) in addition to drug therapy (tolterodine) for urgency incontinence. Compared with drug therapy alone, combined therapy was more successful, defined by a greater than 70% reduction in incontinence episodes (58% for drug therapy vs 69% for combined therapy). The rates of continued drug use were not different (41%) at 8 months.
41
Strong evidence supports the recommendation for weight loss in overweight women with incontinence. A randomized clinical trial of a 6-month structured weight loss program vs education alone in 338 overweight and obese women reported a 47% reduction in mean incontinence episodes compared with a 28% reduction in the control group (P = .01). 44 The treatment group had a mean 7.8-kg reduction in weight (8%) vs a mean 1.5-kg reduction (1.6%) in the control group, and these patients were more likely than controls to have a clinically meaningful reduction in all incontinence episodes (47% vs 28%; P < .01). Women in the treatment group experienced a decrease in weekly incontinence episodes, from a baseline mean (SD) of 24 (18) episodes to 13 (15) episodes. The effect was more pronounced for stress incontinence, with a reduction from 9 (11) to 4 (7) episodes (58% vs 33%; P = .02).
44
Pelvic Floor Muscle Exercise Systematic reviews consistently report efficacy for pelvic floor muscle exercises for women with urinary incontinence. [45] [46] [47] [48] [49] [50] Although there are no significant risks or expenses for unsupervised exercises, they require personal engagement and time commitment. Clinicians can provide simple exercise instructions for the patient if she is able to contract her pelvic floor muscle. Thirty contractions per day (3 sets of 10 contractions held for 10 seconds each) is typically recommended; patients should not be instructed to interrupt their urine stream while performing their daily exercises. There are numerous modalities to assist with pelvic floor muscle exercises, but there is insufficient evidence to suggest that any specific exercise program is superior to another. 50 A systematic review of clinical trials focusing on 12-month outcomes for supervised pelvic floor muscle training reported stress urinary incontinence cure rates of 58.8% at 12 months. Patients considered cured reported being completely continent or had no evidence of stress urinary incontinence on physical testing, with a significant reduction in their incontinence episodes. 51 The addition of vaginal weighted cones, biofeedback, or other feedback may improve these cure rates over exercise alone. 48, 49 Women should be encouraged to pursue a modality that facilitates compliance.
There is some evidence that bladder control pessaries are effective and may be preferable for women who have stress urinary incontinence during specific situations; for example, only during exercise.
52 Table 2 highlights important, high-impact, stress incontinence treatment trials. In a multicenter randomized trial of pessary vs behavioral therapy with pelvic floor exercises vs combination therapy, 33% of women treated with a pessary reported no bothersome incontinence compared with 49% in the behavioral therapy group (P = .006). Although overall satisfaction at 3 months was higher with the behavioral therapy group (75% vs 63%; P = .02), there were no differences after 12 months, with 50% overall satisfaction. 53 Over-thecounter vaginal insert devices, such as Impressa, may provide an alternativenoninvasivetreatment,althoughcomparativedataarelacking. The addition of vaginal devices to pelvic floor exercises is not more effective than either modality alone. 50,53 A recent randomized trial from China reported the efficacy of acupuncture for stress incontinence. 60 Future studies will be needed to determine the role 380 (58) 77 (26) 77 ( of acupuncture for women in the United States, given the limited availability and lack of insurance coverage.
Medications
There are no FDA-approved medications for stress incontinence. There are 6 FDA medications in the primary medication class for urgency incontinence (darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium). These medications are used as second-line treatment. 32 Table 3 displays the magnitude of improvements reported in FDA regulatory trials of medication for treatment of urgency incontinence. Most efficacy data for these medications are from short-term, industry-supported studies with moderate-to high-level evidence to support efficacy compared with placebo. The medications for treating urgency incontinence have not all been directly compared for efficacy or adverse effects. The magnitude of improvements reported in FDA regulatory trials ranges from 53% to 80% reduction in urinary incontinence episodes and 12% to 32% reduction in urinary frequency, with placebo rates of improvement from 30% to 47% for incontinence episodes and 8% to 15% for urinary frequency. Medication selection is generally made according to formulary availability, patient costs, and specific clinical factors. Anticholinergic medications block muscarinic receptors in the smooth muscle of the bladder, thus inhibiting detrusor contraction. These medications are associated with moderate improvements in urgency, frequency, and urgency incontinence episodes. [61] [62] [63] [64] [65] The proportion of patients reporting symptom control with anticholinergic medications is 49% (interquartile range, 35.6%-58%). 51 Discontinuation because of adverse effects (dry mouth and constipation) is common, with less than 50% of patients continuing prescribed medication beyond 6 months and less than 36% beyond 1 year. 66 Patients may prefer the convenience of daily medication or a lower medication cost associated with multiple daily dosing. Once-daily dosing of medication also may improve adherence to treatment. 67 Specialty guidelines recommend using the extended-release formulation over the immediaterelease one to minimize adverse effects.
32
Contraindications to anticholinergic medications include untreated narrow-angle glaucoma (an uncommon condition). This class of drugs may aggravate existing cardiac arrhythmias. Although 2 drugs in this class, solifenacin and tolterodine, are reported to prolong the QT interval, routine electrocardiogram is not recommended before prescribing this medication. Recent research raises questions regarding the association of long-term anticholinergic exposure with dementia. 68 β-3 Agonists are also available for treating urgency incontinence. Stimulation of the β-3 pathway promotes smooth muscle relaxation of the bladder to increase urine storage. Mirabegron, the only FDA-approved drug in this class, has efficacy that is better than placebo's and not different from that of anticholinergics, and has reported symptom control rates of 43.5% to 45.8% at 12 months. 51, 65, 69, 70 Mirabegron's adverse effects include the possibility of increasing hypertension. It may provide synergistic effects with anticholinergic medications in women who have insufficient response with monotherapy. [71] [72] [73] Table 3 displays the rates of the most common adverse effects, constipation and dry mouth, as reported in registration studies of FDA-approved medications for urgency incontinence. A systematic 
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Urinary Incontinence in Women review of 86 trials comparing anticholinergic medications revealed comparisons between different therapies for only 4 drugs: oxybutynin, tolterodine, solifenacin, and fesoterodine. The authors concluded that immediate-release tolterodine may be associated with less dry mouth compared with immediate-release oxybutynin, and extended-release formulations of these drugs should be used in preference to immediate-release ones to minimize dry mouth; solifenacin may have better efficacy than immediate-release tolterodine; and fesoterodine may be more efficacious than extended-release tolterodine, with more adverse effects. There were insufficient data to evaluate other anticholinergics or to compare quality of life, cost, or longterm success. 74 The only studies comparing mirabegron to other drugs have been industry sponsored in the setting of comparing combined therapy (ie, mirabegron plus low-dose solifenacin) vs monotherapy. A recent study demonstrated significant reduction in urgency incontinence episodes with 50 mg mirabegron plus 5 mg solifenacin compared with 5 mg solifenacin alone (71% vs 54%; mean adjusted difference,-0.2;P = .03);however,nosignificantdifferencewasachieved compared with mirabegron 50 mg alone (61% reduction). The study was not designed to compare mirabegron 50 mg vs solifenacin 5 mg alone. The placebo group had a 42% reduction in incontinence episodes, and the 10-mg dose that is typically prescribed for solifenacin was not studied. 73 Local low-dose vaginal estrogens (creams, tablets, or rings) are FDA approved for the treatment of vaginal atrophy. Although nonindustry-sponsored multicenter comparative trials are lacking, systematic reviews suggest modest improvement in urinary incontinence in postmenopausal women compared with placebo. [75] [76] [77] There is no evidence for efficacy of systemic estrogen for treatment of any form of urinary incontinence; systemic estrogen may worsen incontinence. 75 
Procedures Stress Incontinence Surgery
Women whose predominantly stress incontinence symptoms persist despite conservative measures may be candidates for surgery. Table 2 displays important stress incontinence treatment trials. Surgery is highly effective, with median cure rates of 84.4% (interquartile range, 74%-90.1%) at 12 months. 51 Historically, the standard surgery for stress incontinence included a retropubic urethropexy or a pubovaginal sling. A multicenter randomized controlled trial of these 2 procedures in 655 women revealed higher stress-incontinencespecific success rates (66% vs 49%; P < .001) but higher morbidity (6.1% vs 0% voiding dysfunction requiring reoperation) for the pubovaginal sling compared with urethropexy. 56,57 A European randomized trial of retropubic Burch colposuspension vs retropubic midurethral sling in 344 women revealed no difference in success rates at 6 months and 5 years. 54, 55 Currently, the most commonly performed surgery is the midurethral sling, a 30-minute outpatient procedure in which a synthetic mesh sling is placed through either a retropubic or transobturator approach. 78, 79 The midurethral sling is the most extensively studied anti-incontinence operation, with documented short-term efficacy (62% to 98%) and longterm efficacy (>5 years: 43% to 92%). 79, 80 Complication rates are Women with stress incontinence can undergo urethral bulking injection, typically in an office setting under local anesthesia with a cystoscope. The bulking material is injected under the urethral mucosal layer to increase outflow resistance. High-quality multicenter randomized trials are lacking, but systematic reviews suggest lower success rates compared with that for sling procedures. 81, 82 Cure rates for injectable bulking agents have been reported in 24.8% to 36.9% of women at 12-month follow-up.
51
Urgency Incontinence Procedures
There are 3 FDA-approved procedural treatments for women with persistent urgency incontinence symptoms or intolerance to medication. All of these treatments are based on changes in neural regulation. Percutaneous tibial nerve stimulation is an office procedure in which electrical stimulation via an acupuncture needle is delivered in twelve 30-minute weekly sessions, followed by monthly maintenance therapy. Industry-supported studies of percutaneous tibial nerve stimulation have reported subjective improvement of 60% (95% CI, 49%-75%), with low rates of transient local adverse events (8.5%) and efficacy similar to that of anticholinergic medications.
83-85
OnabotulinumtoxinA (100 U) is injected into the bladder through a cystoscope with local anesthetic in an office setting. The drug blocks the presynaptic release of acetylcholine to decrease muscarinic receptor activation involved in detrusor contraction. Treatment is effective in approximately 65% of participants for approximately 6 to 12 months. 42 Treatment risks include urinary retention (8%-10%) and urinary tract infections (35%). A large multicenter clinical trial of oral anticholinergic medication demonstrated reductions in incontinence episodes similar to those with onabotulinumtoxinA (100 U) (68% and 66%, respectively) ( Table 2) . 86 More participants reported resolution of urge urinary incontinence after treatment with onabotulinumtoxinA (13% vs 27%; P = .003). Sacral neuromodulation is an outpatient surgical procedure in which an implanted electrode is placed along the third sacral nerve root to deliver nerve stimulation. When a short-term test is successful, a permanent external stimulator that lasts approximately 5 years can be implanted. After implantation, approximately 60% to 90% of women report improvement and 30% to 50% report cure. 87 A recent multicenter randomized trial of onabotulinumtoxinA, 200 U, compared with sacral neuromodulation demonstrated a small but statistically significant superiority for onabotulinumtoxinA in the reduction of urgency incontinence episodes at 6 months (−3.9 [72%] vs −3.3 [63%], P = .01)] (Table 1) . 43 Urinary tract infections (35% vs 11%) and need for catheterization (8% vs 0%) were more frequent with onabotulinumtoxinA, whereas device revisions and removals occurred in 3% of patients.
Conclusions
Urinary incontinence is common in women, although few seek care despite many effective treatment options. Clinicians should prioritize urinary incontinence detection, identify and treat modifiable factors, incorporate patient preference into evaluation and treatment, initiate conservative and medical therapy, and refer to specialists when underlying pathology is identified or conservative measures are ineffective.
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